Danaher Corporation's Biotechnology segment reported second-quarter 2026 sales of $1.92 billion, up 4% year over year, with core revenues increasing 2.5%. The growth was driven by stronger demand in China, higher consumables and equipment sales in bioprocessing, and improved discovery and medical business. However, difficult prior-year comparisons in Western Europe and North America and shipment timing shifts by large customers remain concerns. Danaher expects the segment's core revenues to grow in the mid-single digits in 2026. Shares of Danaher have gained 24.4% in the past month, and the company carries a Zacks Rank #3 (Hold).
Danaher CorporationBiotech segment sales rose 4% on stronger China demand and higher consumables/equipment sales.
Laboratory Corporation of America Holdings
CVS Health Corp